ada standards of care 2025 obesity pharmacotherapy glp-1 recommendations The pharmacological management Type 2 Diabetes, adapted from guidelines, focusing on treatment initiation and intensification based on patient comorbidities and glycemic control ADA 2025 Diabetes Management: CGM

This dual mechanism is believed to explain why Tirzepatide achieves: Greater HbA1c reductions (up to 2.5%) More significant weight loss (up to 22% body weight in some studies) Ongoing Research and Implications Tirzepatides mechanism opens the door to multi-target metabolic therapya promising future direction for treating not only type 2 diabetes, but also obesity, fatty liver disease (NAFLD), and cardiovascular risks

The shopping journey and changes in shopping behavior move away from just a transactional one to much more of an emotional one

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF)

Yin J., et al